Praxis Precision Medicines, Inc. Common Stock
PRAX
$350.30
+1.61%
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, leveraging its proprietary Cerebrum and Solidus platforms. The company is a niche player in the precision medicine space, with a diversified pipeline targeting movement disorders and epilepsy, including lead candidates Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The current investor narrative centers on the FDA's acceptance of its drug application for essential tremor, which has catalyzed a massive stock surge and attracted significant institutional investment, though the company remains pre-revenue and faces high regulatory and clinical risk. The stock's extraordinary 1-year performance reflects optimism about potential approvals and the substantial market opportunity, but also raises questions about valuation sustainability.…
PRAX
Praxis Precision Medicines, Inc. Common Stock
$350.30
Related headlines
Investment Opinion: Should I buy PRAX Today?
Based on the analysis, I rate PRAX as a 'Buy' for investors with a high risk tolerance. The thesis is that the FDA acceptance for essential tremor and the strong pipeline justify the current valuation, with substantial upside to the analyst average target of $638.68 (85.2% upside). The consensus rating is 'Strong Buy' with a mean score of 1.47, indicating broad analyst support.
Sign up to view all
PRAX 12-Month Price Forecast
The AI assessment leans bullish due to the strong regulatory momentum and analyst support, but confidence is medium given the extreme valuation and pre-revenue status. The stock's 649.6% surge over the past year suggests high expectations, and any negative news could lead to a sharp correction. The key factors to watch are the FDA's decision timeline and clinical trial results. If the FDA approval is secured and revenue begins to flow, the stock could reach the bull case target. However, if setbacks occur, the downside is substantial. The stance would be upgraded to high confidence if the company reports positive phase 3 data or secures a partnership, and downgraded to neutral if the FDA delays or a trial fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Praxis Precision Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $638.68 and implied upside of +82.3% versus the current price.
Average Target
$638.68
0 analysts
Implied Upside
+82.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$188 - $1201
Analyst target range
Praxis Precision Medicines is covered by 19 analysts, with a consensus recommendation of 'Strong Buy' (mean score of 1.47 on a 1-5 scale, where 1 is strong buy). The average target price is $638.68, implying a substantial upside of 85.2% from the current price of $344.75. The analyst sentiment is overwhelmingly bullish, with no sell ratings and only one underperform rating (from Wedbush), reflecting strong conviction in the company's pipeline and regulatory progress.
Drowning in data?
Find the real signal!
Bulls vs Bears: PRAX Investment Factors
Praxis Precision Medicines presents a high-risk, high-reward opportunity. The bull case is anchored by FDA acceptance for essential tremor, strong analyst support, and a diversified pipeline, while the bear case highlights the pre-revenue status, escalating losses, and extreme valuation premium. Currently, the bull side has stronger evidence given the regulatory momentum and institutional backing, but the stock's valuation leaves no margin for error. The most critical tension is whether the pipeline's commercial potential can justify the current market cap of $6.6 billion, especially given the lack of revenue and high cash burn. Any setback in clinical trials or regulatory process could lead to a severe correction.
Bullish
- FDA Acceptance for Essential Tremor: The FDA accepted Praxis's drug application for essential tremor, setting a clear path to a potential 2027 approval. This regulatory milestone validates the clinical data and reduces near-term approval risk, a major catalyst for the stock.
- Strong Analyst Conviction: With 19 analysts covering the stock, the consensus is 'Strong Buy' (mean score 1.47). The average target price is $638.68, implying 85.2% upside from the current price of $344.75, reflecting high confidence in the pipeline's commercial potential.
- Massive Institutional Investment: A major biotech investor has increased its stake to nearly $600 million, and another fund invested $266 million, signaling strong conviction in the pipeline. This institutional backing provides financial stability and validates the company's prospects.
- Diversified CNS Pipeline: Praxis has four clinical-stage candidates (Ulixacaltamide, Relutrigine, Vormatrigine, Elsunersen) targeting movement disorders and epilepsy. This diversification reduces single-asset risk and offers multiple shots on goal for future growth.
Bearish
- Pre-Revenue with Escalating Losses: Praxis has zero revenue in Q1 2026, and net losses widened to -$92.56 million from -$69.30 million a year ago, a 33.6% increase. The company is burning cash at an accelerating rate, with negative free cash flow of -$282.9 million TTM, raising sustainability concerns.
- Extreme Valuation Premium: The price-to-book ratio of 7.55 is significantly above its historical average of ~2.5, indicating the market is pricing in substantial future success. This premium leaves little room for error, and any clinical setback could trigger a sharp de-rating.
- High Volatility and Beta: With a beta of 2.776, the stock is highly sensitive to market swings. The 52-week range of $37.19 to $392.70 illustrates extreme volatility, and the recent -6.28% drop in a single day highlights the risk of sharp drawdowns.
- Regulatory and Clinical Risk: As a clinical-stage biotech, Praxis faces inherent risks of trial failures, regulatory delays, or safety issues. The FDA acceptance is positive, but approval is not guaranteed, and any negative news could devastate the stock.
PRAX Technical Analysis
Praxis Precision Medicines has exhibited a powerful long-term uptrend, with the stock price soaring 649.6% over the past year, dramatically outperforming the S&P 500's 18.6% gain. The current price of $344.75 sits at 87.8% of its 52-week range (between $37.19 low and $392.70 high), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The 52-week low of $37.19 was set in early 2025, and the stock has since rallied to a high of $392.70 in August 2026, reflecting a remarkable recovery and sustained bullish sentiment.
Beta
2.78
2.78x market volatility
Max Drawdown
-33.4%
Largest decline past year
52-Week Range
$37-$393
Price range past year
Annual Return
+669.2%
Cumulative gain past year
| Period | PRAX Return | S&P 500 |
|---|---|---|
| 1m | +13.8% | +2.7% |
| 3m | +35.7% | +1.0% |
| 6m | +7.7% | +12.0% |
| 1y | +669.2% | +18.9% |
| ytd | +22.3% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PRAX Fundamental Analysis
Praxis Precision Medicines is a pre-revenue biotech, with zero revenue reported in the most recent quarter (Q1 2026) and only minimal revenue in prior quarters (e.g., $7.46 million in Q4 2024, $0.30 million in Q3 2024). The company's net loss widened to -$92.56 million in Q1 2026 from -$69.30 million in Q1 2025, representing a 33.6% increase in losses year-over-year, driven by higher R&D expenses of $77.99 million. The lack of revenue and escalating losses underscore the company's dependence on successful clinical development and regulatory approvals for future growth.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-282905000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PRAX Overvalued?
Given that Praxis Precision Medicines has negative net income and negative EBITDA, the price-to-sales (PS) ratio is not meaningful due to negligible revenue, and the EV/EBITDA is also negative (-20.7). Therefore, the most appropriate valuation metric is the price-to-book (PB) ratio, which stands at 7.55, reflecting the market's premium for its pipeline assets. The trailing PE is -21.86 and forward PE is -37.09, both negative, indicating the market expects continued losses. The PB ratio of 7.55 is significantly higher than the historical average of around 2.5 over the past two years, suggesting the stock is trading at a substantial premium to its book value, which may be justified by the potential of its CNS pipeline but also implies high expectations.
PE
-21.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Praxis is pre-revenue with zero sales in Q1 2026, and its net loss widened to -$92.56 million, a 33.6% increase year-over-year. The company's free cash flow is deeply negative at -$282.9 million TTM, indicating heavy reliance on external financing. While the current ratio of 10.22 provides near-term liquidity, the escalating R&D expenses (e.g., $77.99 million in Q1 2026) suggest the cash runway may be limited without additional capital raises, which could dilute existing shareholders. The negative EBITDA of -$92.5 million and negative PE ratios underscore the lack of profitability and the dependence on successful clinical development to generate future revenue.
